Table 1 Demographic characteristics and clinical parameters of RSV-associated SARI patients, Senegal January-December 2022.

From: Respiratory syncytial virus in pediatric patients with severe acute respiratory infections in Senegal: findings from the 2022 sentinel surveillance season

RSV positive

Overall

Total tested (n = 748)

Crude OR

Adjusted OR

RSV A

RSV B

Untyped RSV

p-value

Characteristics

(n = 120)

(n = 12)

(n = 107)

(n = 1)

 

(95% CI)

(95% CI)

Gender, n (%)

 Male

55 (45.8)

6 (50.0)

49 (45.8)

0 (0.0)

1

1

1

 Female

65 (54.2)

6 (50.0)

58 (54.2)

1 (100)

0.1

0.73 [0.5—1.1]

0.69 [0.45—1.05]

Age group, n (%)

 ≤ 11 months

100 (83.3)

11 (91.7)

88 (82.2)

1 (100)

1

1

1

 1–2 years

11 (9.2)

1 (8.3)

10 (9.3)

0 (0.0)

5.63 e−05

0.3 [0.1—0.5]

0.28 [0.15–0.5]

 3–5 years

5 (4.2)

0 (0.0)

5 (4.7)

0 (0.0)

0.001

0.1 [0.03–0.4]

0.15 [0.036–0.4]

 6–10 years

2 (1.7)

0 (0,0)

2 (1.9)

0 (0,0)

0.007

0.07 [0.004–0.3]

0.06 [0.003–0.3]

 11–15 years

0 (0.0)

0 (0,0)

0 (0.0)

0 (0.0)

0.9

–

–

 > 15

1 (0.8)

0 (0,0)

1 (0.9)

0 (0,0)

0.001

0.04 [0.002–0.17]

0.03 [0.002–0.16]

 Mean age (95% CI)

0.8 [0.3–1.4]

0.2 [0–0.3]

0.9 [0.3–1.5]

–

 

–

–

Clinical manifestation, n (%)

 Fever

52 (43.3)

12 (100)

107 (100)

1 (100)

0.0003

0.48 [0.32—0.72]

0.46 [0.31—0.69]

 Cough

91 (75.8)

12 (100)

107 (100)

1 (100)

0.62

1.12 [0.72—1.78]

1.12 [0.71—1.79]

 Breathing difficulties

97 (80.8)

11 (91.7)

85 (79.4)

1 (100)

0.004

2.01 [1.26—3.33]

2.02 [1.27—3.37]

 Rhinitis

6 (5.0)

0 (0,0)

5 (4.7)

0 (0.0)

0.96

0.98 [0.36—2.24]

0.95 [0.35—2.19]

 Vomiting

2 (1.2)

0 (0,0)

2 (1.9)

0 (0.0)

0.51

0.61 [0.09–2.16]

0.61 [0.09–2.16]

LRT complications, n (%)

 Pneumonia

37 (30.8)

3 (25.0)

33 (30.8)

1 (100)

 < 2.2e−16

–

–

 Bronchiolitis

69 (57.5)

8 (66.7)

61 (57.0)

0 (0.0)

 < 2.2e−16

–

–

 Acute bronchitis

8 (6.7)

1 (8.3)

7 (6.5)

0 (0.0)

1.73e−09

–

–

 Asthma exacerbation

11 (9.2)

1 (8.3)

10 (9.3)

0 (0.0)

4.83e−13

–

–

Prescribed treatment, n (%)

Antibiotics

78 (65.0)

10 (83.3)

67 (62.6)

1 (100)

 < 2.2e−16

–

–

Bronchodilators

40 (33.3)

3 (25.0)

37 (34.6)

0 (0.0)

 < 2.2e−16

–

–

  1. n number of patients, LRT lower respiratory tract, RSV respiratory syncytial virus.
Back to article page